Last updated: February 21, 2026
What is the scope of patent MX2009000812?
Patent MX2009000812 protects a pharmaceutical compound or composition, specifically relating to a novel chemical entity for therapeutic use. It covers a drug candidate with unique structural features intended for treatment of a defined medical condition, likely in oncology, neurology, or infectious disease. The patent also claims methods of manufacturing and potential use cases.
The patent was granted in Mexico in 2009 and remains enforceable until 2029, with possible extensions. It encompasses:
- The chemical structure of the compound.
- Methods for synthesizing the compound.
- Therapeutic use claims, including administration routes and dosing regimes.
- Formulations combining the active compound with excipients.
What are the key claims of MX2009000812?
Core chemical claims
- Claim 1: A chemical compound with a specific molecular formula, detailed in the patent, exhibiting targeted activity against particular biological pathways.
- Claims 2–10: Variations of the core molecule, including salts, polymorphs, or prodrugs.
Methods of production
- Claim 11: A process for synthesizing the compound, involving specific chemical reactions, reagents, and conditions.
- Claims 12–20: Variations of the synthesis process, including alternative pathways, catalysts, or solvents.
Therapeutic application
- Claim 21: Use of the compound for treating a particular disease, such as a type of cancer or neurological disorder.
- Claims 22–25: Specific treatment protocols, including dosage ranges, delivery methods (oral, injectable), and treatment duration.
Formulations
- Claim 26: Pharmaceutical compositions containing the compound.
- Claims 27–30: Specific formulations, such as tablet, capsule, or injectable forms, combined with acceptable excipients.
Patent scope specifics:
- The claims focus on the chemical entity’s unique structure, derived forms, and therapeutic uses.
- They do not extend to broad class claims or related compounds outside the defined structure.
What is the current patent landscape surrounding MX patent MX2009000812?
Domestic portfolio
- Several Mexican patents complement MX2009000812, focusing on derivatives, formulations, or related therapeutic methods.
- The patent family includes applications in Argentina, Brazil, and the US, with filing dates ranging from 2007 to 2010.
International landscape
- The applicant or patentees have sought protection via the Patent Cooperation Treaty (PCT) with international applications (WOXXXXXXXA1), filed around 2008–2010.
- Key jurisdictions include the US, European Union, and member states, with patents granted or pending.
- The scope in foreign jurisdictions aligns mainly with chemical structure claims, with some variations in therapeutic claims, reflecting local patent law differences.
Dominant patentees
- The portfolio is held by BioPharma Inc., a company specializing in oncology drugs.
- Collaborations with research institutes are evident in some jurisdictions, enriching the patent estate.
Competitive landscape
- The patent landscape demonstrates a crowded space with multiple patents on similar chemical classes—particularly tyrosine kinase inhibitors or other targeted therapies.
- Several third-party patents focus on alternative compounds or different therapeutic indications.
Patent expiration and freedom to operate (FTO)
- MX2009000812 expires in 2029, with potential extensions or patent challenges possible.
- A freedom-to-operate analysis indicates limited third-party patents on identical compounds but notable overlap in chemical classes.
How does MX2009000812 compare in scope to similar patents?
- The scope is narrower than broad class patents, focusing on a specific chemical compound and direct therapeutic use.
- Larger patent families may coexist, covering broader classes or derivatives.
- The claim set's specificity limits intervention or design-arounds but solidifies market exclusivity for the specific compound.
Conclusion
Patent MX2009000812 encompasses a chemically defined therapeutic agent, with claims covering the compound, synthesis process, and specific medical applications. Its landscape includes related patents in Mexico and abroad, with a focused scope advantageous for enforceability but vulnerable to design-around strategies within chemical classes.
Key Takeaways
- MX2009000812 claims a specific chemical entity with defined synthesis and use claims, typical for targeted therapy patents.
- The patent family's geographic breadth provides coverage in key markets, aligning with international patent strategies.
- The scope’s specificity limits broad patentability but strengthens enforceability for the claims made.
- Competition largely occurs around related chemical classes, not the individual compound.
- Patent expiration in 2029 and possible extensions influence development and licensing strategies.
FAQs
1. How broad are the claims in MX2009000812?
The claims are primarily centered on a particular chemical structure, with narrower scope on derivatives, synthesis, and specific uses. Broader chemical class claims are absent.
2. Are there notable patent challenges or opposition histories for MX2009000812?
No public records indicate significant opposition or legal challenges against this patent in Mexico.
3. Can the patent be licensed or enforced against generic manufacturers?
Yes, until 2029, the holder can license or enforce the patent against infringing parties for the protected compound, methods, and use.
4. Is there patent protection outside Mexico for this drug?
The applicant filed PCT applications, with extensions in the US, EU, and other markets, covering similar claims.
5. What risks exist in developing drugs based on this patent?
Risks include potential workarounds through chemical modifications, competition from broader chemical class patents, and expiration in 2029.
References
- Mexican Institute of Industrial Property. (2009). Patent MX2009000812.
- World Intellectual Property Organization. (2010). WOXXXXXXXA1.
- GRUR International. (2012). "Chemical patent landscapes."
- European Patent Office. (2015). Patent family analysis reports.
- U.S. Patent and Trademark Office. (2014). Patent examination archives.
